First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

NCT06128382 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus

Interventions

BIOLOGICAL: OVX033
BIOLOGICAL: Saline solution

Sponsor

Osivax

Collaborators

[object Object]